Payment overview · 2025
General Payments
$751.28
42 reported records · 17 companies
Healthcare provider profile · identity verified
Robert J Karl, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HENDERSON, NV · NPI 1073595435
Verified facts
What the public records show
CMS Open Payments records show Robert J Karl, M.D. received $751.28 in general payments during 2025 across 42 reported records.
Corcept Therapeutics accounted for 11.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $89.04 | 11.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.88 | 11.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.70 | 11.4% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $84.12 | 11.2% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.17 | 8.9% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $65.23 | 8.7% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $50.78 | 6.8% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $46.74 | 6.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.63 | 4.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.52 | 3.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.14 | 2.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.10 | 2.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.91 | 2.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.67 | 2.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $15.46 | 2.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.52 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.67 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $751.28 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $89.04 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.70 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $84.12 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $67.17 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $66.35 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.82 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.82 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $46.74 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $36.06 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 106 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 413 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 116 |
| Omeprazole | Omeprazole | 321 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 83 |
| Losartan Potassium | Losartan Potassium | 247 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 64 |
| Lisinopril | Lisinopril | 169 | 63 |
| Celecoxib | Celecoxib | 148 | 55 |
| Metformin Hcl | Metformin Hcl | 145 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 47 |
| Carvedilol | Carvedilol | 138 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 53 |
| Montelukast Sodium | Montelukast Sodium | 131 | 47 |
| Gabapentin | Gabapentin | 130 | 42 |
| Trazodone Hcl | Trazodone Hcl | 128 | 45 |
| Meloxicam | Meloxicam | 126 | 48 |
| Allopurinol | Allopurinol | 116 | 40 |
| Ozempic | Semaglutide | 112 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 35 |
| Eliquis | Apixaban | 106 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 38 |
| Sertraline Hcl | Sertraline Hcl | 99 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 29 |
| Furosemide | Furosemide | 85 | 36 |
| Ezetimibe | Ezetimibe | 81 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 80 | 25 |
| Alprazolam | Alprazolam | 78 | 14 |
| Simvastatin | Simvastatin | 76 | 28 |
| Azithromycin | Azithromycin | 71 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | suppressed |
| Pregabalin | Pregabalin | 67 | 20 |
| Spironolactone | Spironolactone | 67 | 26 |
| Clonazepam | Clonazepam | 64 | 13 |
| Prednisone | Prednisone | 64 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 33 |
| Tramadol Hcl | Tramadol Hcl | 60 | 20 |
| Bupropion Xl | Bupropion Hcl | 59 | 20 |
| Lorazepam | Lorazepam | 59 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 58 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 20 |
| Valsartan | Valsartan | 54 | 18 |
| Potassium Chloride | Potassium Chloride | 53 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 21 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Topiramate | Topiramate | 47 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 14 |
| Estradiol | Estradiol | 41 | 18 |
| Glimepiride | Glimepiride | 41 | 12 |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 40 | 14 |
| Benazepril Hcl | Benazepril Hcl | 37 | 14 |
| Farxiga | Dapagliflozin Propanediol | 37 | 13 |
| Atenolol | Atenolol | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 29 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 35 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 30 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Famotidine | Famotidine | 30 | 16 |
| Alendronate Sodium | Alendronate Sodium | 28 | 12 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Linzess | Linaclotide | 22 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | 13 |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Colchicine | Colchicine | 15 | 11 |
| Methylprednisolone | Methylprednisolone | 15 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 12 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 11 |
| Fluconazole | Fluconazole | 14 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $751.28 · 42 records | Corcept Therapeutics | BREZTRI, CAPLYTA, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, INJECTAFER, KRYSTEXXA, Kerendia, Korlym, LEQVIO, Leqembi, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SPRAVATO, Symbravo, VOQUEZNA, Wegovy, XYOSTED, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error